본문 바로가기

Time to appropriate treatment in patients with multidrug-resistant tuberculosis in South Korea: Are we still in 2010?

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q1
저널
PLOS ONE14(4) · 2019
피인용
Web of Science 5Scopus 5
FWCI (Scopus)
0.21
JCR IF
JCR 2018 2.776
ISSN
1932-6203

저자

  1. 조은정제1저자Department of Internal Medicine, Pusan National University Hospital, Busan, Korea
  2. 박세연Department of Internal Medicine, Pusan National University Hospital, Busan, Korea
  3. 이규민Department of Internal Medicine, Pusan National University Hospital, Busan, Korea
  4. 김인수Department of Internal Medicine, Pusan National University Hospital, Busan, Korea
  5. 엄중섭Department of Internal Medicine, Pusan National University Hospital, Busan, Korea
  6. 김미현College of Medicine, Pusan National University, Yangsan, Korea
  7. 이광하College of Medicine, Pusan National University, Yangsan, Korea
  8. 김기욱College of Medicine, Pusan National University, Yangsan, Korea
  9. 박혜경College of Medicine, Pusan National University, Yangsan, Korea
  10. 이민기College of Medicine, Pusan National University, Yangsan, Korea
  11. 목정하교신저자College of Medicine, Pusan National University, Yangsan, Korea

초록

Background This study investigated the time to appropriate treatment and factors affecting late treatment initiation in patients with multidrug-resistant tuberculosis (MDR-TB) in South Korea. Methods Data from patients with culture-confirmed pulmonary MDR-TB who received treatment at Pusan National University Hospital (PNUH) between January 2010 and July 2018 were reviewed retrospectively. Patients were divided into two groups according to the first institution they visited [patients who were transferred to PNUH after diagnosis of MDR-TB (Group A) and patients who were initially diagnosed with TB at PNUH (Group B)]. Results A total of 100 patients were included (53 in Group A and 47 in Group B). The percentage of patients in whom line probe assays (LPAs) for isoniazid and rifampin or Xpert MTB/RIF assays were performed was higher in Group B than in Group A [20.8 vs. 57.4% (P < 0.001) and 17.0 vs. 46.8% (P = 0.001), respectively]. The median time from the first visit to appropriate treatment initiation was longer in Group A (102.0 vs. 77.0 days, P = 0.002). However, a subgroup analysis of patients with pre-extensively or extensively drug-resistant TB (pre-XDR- or XDR-TB) revealed that the time to appropriate treatment did not differ between Groups A and B. Although the time to appropriate treatment decreased during the study period in both Groups A and B, this trend was not evident in patients with pre-XDR- or XDR-TB in Group B. Based on multivariate analyses, performance of LPAs for isoniazid and rifampin, performance of Xpert MTB/RIF assays, and the presence of uncomplicated MDR-TB were protective against delays in appropriate treatment initiation. Conclusions The time to appropriate treatment in patients with MDR-TB in South Korea was not acceptable, particularly for patients diagnosed outside of PNUH and for patients with pre-XDR- or XDR-TB. The use of rapid molecular drug susceptibility tests in various healthcare settings and introduction of second-line LPAs are required.

키워드

EXTENSIVELY DRUG-RESISTANTMYCOBACTERIUM-TUBERCULOSISINITIATIONASSAY

식별자

Scopus EID
2-s2.0-85064891392
WoS UID
000465519100090